We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
-$325M
Cap. Flow
-$296M
Cap. Flow %
-19.34%
Top 10 Hldgs %
65.86%
Holding
300
New
43
Increased
68
Reduced
83
Closed
84

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.6M
2
TSRO
TESARO, Inc.
TSRO
+$7.45M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$5.41M
4
MBOT icon
Microbot Medical
MBOT
+$4.73M
5
UTHR icon
United Therapeutics
UTHR
+$4.46M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$6.09M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$5.39M
3
MTFB
Motif Bio plc ADRs
MTFB
+$4.6M
4
OTIC
Otonomy, Inc.
OTIC
+$3.19M
5
PALI icon
Palisade Bio
PALI
+$2.63M

Sector Composition

Rank Sector Weight
1 Healthcare 13%
2 Materials 0.27%
3 Financials 0.11%
4 Consumer Staples 0.03%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
276
PUT
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-931
Closed -$439K
XLRN
277
CALL
DELISTED
Acceleron Pharma
XLRN
– –
-92
Closed -$244K
GWPH
278
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-1,074
Closed -$13M
WMGI
279
CALL
DELISTED
Wright Medical Group Inc
WMGI
– –
-535
Closed -$1.67M
PTLA
280
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-3,560
Closed -$14M
PTLA
281
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-107
Closed -$419K
CORV
282
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
– –
-273,010
Closed -$819K
FOMX
283
CALL
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-184
Closed -$91K
FOMX
284
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-35,037
Closed -$173K
AVEO
285
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-86,890
Closed -$513K
GNMX
286
CALL
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-450
Closed -$84K
GNMX
287
DELISTED
Aevi Genomic Medicine Inc
GNMX
– –
-19,888
Closed -$37K
MTFB
288
DELISTED
Motif Bio plc ADRs
MTFB
– –
-755,875
Closed -$4.6M
FWP
289
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-4,857
Closed -$733K
IPCI
290
DELISTED
Intellipharmaceuticals International Inc.
IPCI
– –
-2,041
Closed -$51K
MON
291
CALL
DELISTED
Monsanto Co
MON
– –
-313
Closed -$3.54M
AVXS
292
CALL
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-300
Closed -$2.28M
CASC
293
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-161,670
Closed -$669K
RXDX
294
DELISTED
Ignyta, Inc.
RXDX
– –
-95,918
Closed -$779K
RNVAZ
295
DELISTED
Rennova Health, Inc. Warrant
RNVAZ
– –
-5,249,822
Closed -$105K
DRWI
296
DELISTED
DragonWave Inc
DRWI
– –
-466,696
Closed -$677K
ZGNX
297
DELISTED
Zogenix, Inc.
ZGNX
– –
-57,700
Closed -$725K
CYTR
298
DELISTED
CytRx Corp
CYTR
– –
-164,933
Closed -$564K
BDSI
299
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-673,342
Closed -$1.28M
IMUC
300
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
– –
-139,912
Closed -$445K
8 9 10 11
12

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sabby Management held 300 positions worth $1.53B, down 18% from $1.85B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $296M in Q2 2017, closing 84 positions and reducing 83 holdings. Its most notable exit was Amgen, an estimated $6.09M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 6.3% a quarter earlier, followed by Materials and Financials.

Against the trend, Sabby Management opened a new position in TESARO, Inc. worth $7.19M.

  • Sabby Management's largest Q2 2017 buy was TESARO, Inc.: 51,426 shares worth $7.19M.
  • Sabby Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $95.6M increase.
  • Sabby Management's biggest Q2 2017 reduction was Otonomy, Inc., cutting an estimated $3.19M.
  • Sabby Management fully exited Amgen in Q2 2017, selling an estimated $6.09M.
  • Sabby Management's ten largest holdings make up 66% of its $1.53B portfolio in Q2 2017.
  • Sabby Management opened 43 new positions and closed 84 in Q2 2017.
  • Sabby Management's portfolio value fell 18% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.